07
Apr
Category: main
05
Apr
Phase 3 Clinical trials of Taphalgin have commence for patients suffering with postoperative pain.
24
Mar
PVP Labs Group has been established in the UAE, to develop the market for PVP products in the Middle East, India, and Africa.
10
Feb
PVP Labs has established Taph Corporation in the United States, with the primary goal of further developing the market for Taphalagin in America. Taphalgin is PVP’s non-narcotic pain management drug; patented in the US and Canada.
21
Dec
PVP Labs discovers – a life-saving solution that can be used during the early phase of viral infections, to assist humanity in its’ struggle against the viral spread
The problem and relevance of our drug development The outbreak of viral infectious diseases has constantly accompanied humanity. Acute respiratory viral infections (ARVI) are currently the most common type of infectious diseases. According to WHO, there are approximately 300 respiratory viral pathogens, and the viral threat continues to grow. The emergence of new SARS-CoV-2 andRead more about PVP Labs discovers – a life-saving solution that can be used during the early phase of viral infections, to assist humanity in its’ struggle against the viral spread[…]
25
Nov
The TAPHALGIN and ARVIDAL Trademarks have been granted legal protection in more than 30 countries around the world.
13
Nov
PVP Labs was a finalist in the WIPO-IPOS IP FOR INNOVATION AWARDS 2021 in Singapore
02
Apr
PVP Labs signs an MOU with FITT Akza Indonesia, and Swiss Pharma Can (www.swisspharmacan.ch/) for “Cooperation, Development and Research of Arvidal to Combat Covid-19”.
02
Feb
Taphalgin enters phase II clinical trials
02
Dec
